Literature DB >> 22186934

Breast cancer: Increasing therapy options for HER2-positive early breast cancer.

Nadia Harbeck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22186934     DOI： 10.1038/nrclinonc.2011.193

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.

Authors:  Heather L McArthur; Kathleen M Mahoney; Patrick G Morris; Sujata Patil; Lindsay M Jacks; Jane Howard; Larry Norton; Clifford A Hudis
Journal:  Cancer       Date:  2011-06-16       Impact factor: 6.860

Review 2.  Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.

Authors:  N Harbeck; M S Ewer; M De Laurentiis; T M Suter; S M Ewer
Journal:  Ann Oncol       Date:  2010-11-26       Impact factor: 32.976

3.  Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?

Authors:  C M Kelly; K I Pritchard; M Trudeau; E Andreopoulou; K Hess; L Pusztai
Journal:  Ann Oncol       Date:  2011-03-15       Impact factor: 32.976

4.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

5.  Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.

Authors:  Jens Huober; Gunter von Minckwitz; Carsten Denkert; Hans Tesch; Erich Weiss; Dirk Michael Zahm; Antje Belau; Fariba Khandan; Maik Hauschild; Christoph Thomssen; Bernhard Högel; Silvia Darb-Esfahani; Keyur Mehta; Sibylle Loibl
Journal:  Breast Cancer Res Treat       Date:  2010-08-10       Impact factor: 4.872

6.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

Review 8.  Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?

Authors:  Angelo Di Leo; Laura Biganzoli; Wederson Claudino; Sara Licitra; Marta Pestrin; Denis Larsimont
Journal:  Eur J Cancer       Date:  2008-11-05       Impact factor: 9.162

9.  HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

Authors:  Alessandra Gennari; Maria Pia Sormani; Paolo Pronzato; Matteo Puntoni; Mariantonietta Colozza; Ulrich Pfeffer; Paolo Bruzzi
Journal:  J Natl Cancer Inst       Date:  2007-12-25       Impact factor: 13.506
  9 in total
  1 in total

1.  HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro.

Authors:  Xiao-Lin Lin; Xiao-Li Wang; Bo Ma; Jun Jia; Ying Yan; Li-Jun Di; Yan-Hua Yuan; Feng-Ling Wan; Yuan-Li Lu; Xu Liang; Tao Shen; Jun Ren
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.